טוען...
Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
BACKGROUND: Anti-CD19 CAR T cell therapy has demonstrated high response rates in patients with relapsed or refractory (r/r) B cell malignancies but is associated with significant toxicity. Cytokine release syndrome (CRS) is the most significant complication associated with CAR T cell therapy, and it...
שמור ב:
| הוצא לאור ב: | J Hematol Oncol |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5833070/ https://ncbi.nlm.nih.gov/pubmed/29499750 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-018-0571-y |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|